bexarotene has been researched along with Dyslipidemias in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atigadda, VR; Bland, KI; Brouillette, WJ; Deshpande, A; Grubbs, CJ; Kedishvili, N; Krontiras, H; Muccio, DD; Smith, CD; Wu, L; Xia, G | 1 |
| de Haan, W; de Vries-van der Weij, J; Havekes, LM; Hu, L; Kuif, M; Oei, HL; Princen, HM; Rensen, PC; Romijn, JA; Smit, JW; van der Hoorn, JW | 1 |
| Bultel, S; Fiévet, C; Fruchart, JC; Kuipers, F; Lalloyer, F; Lestavel, S; Paumelle, R; Staels, B; Tailleux, A; Torpier, G; Touche, V; van der Veen, J; Yous, S | 1 |
| Avilés Pérez, MD; de Argila Fernández-Durán, D; Díaz Pérez de Madrid, J; Luna López, V; Rodríguez Nevado, I | 1 |
1 trial(s) available for bexarotene and Dyslipidemias
| Article | Year |
|---|---|
Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
Topics: Animals; Anticarcinogenic Agents; Apolipoprotein E3; Bexarotene; Cholesterol Ester Transfer Proteins; Drug Evaluation, Preclinical; Dyslipidemias; Humans; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Mice; Mice, Transgenic; Tetrahydronaphthalenes; Triglycerides | 2009 |
3 other study(ies) available for bexarotene and Dyslipidemias
| Article | Year |
|---|---|
Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.
Topics: Animals; Anticarcinogenic Agents; Binding Sites; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Dyslipidemias; Fatty Acids, Unsaturated; Female; Humans; Mammary Neoplasms, Experimental; Molecular Conformation; Naphthalenes; Rats, Sprague-Dawley; Retinoid X Receptor alpha; Structure-Activity Relationship; Tamoxifen; Triglycerides | 2015 |
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Bexarotene; CD13 Antigens; Cholesterol; Disease Models, Animal; Dyslipidemias; Female; Gene Expression Regulation; Homeostasis; Intestinal Absorption; Lipoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Retinoid X Receptors; Tetrahydronaphthalenes; Triglycerides | 2006 |
[Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders].
Topics: Anticarcinogenic Agents; Bexarotene; Dyslipidemias; Female; Humans; Hypothyroidism; Ligands; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Retinoid X Receptors; Skin Neoplasms; Tetrahydronaphthalenes | 2007 |